Abstract
Original language | English |
---|---|
Pages (from-to) | 2609-2652 |
Number of pages | 44 |
Journal | Diabetologia |
Volume | 64 |
Issue number | 12 |
Early online date | 2021 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Keywords
- Adjunctive therapy
- Diabetic ketoacidosis
- Diagnosis
- Exercise
- Glucose monitoring
- Hypoglycaemia
- Insulin
- Nutrition
- Psychosocial care
- Schedule of care
- Transplantation
- Type 1 diabetes
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Diabetologia, Vol. 64, No. 12, 01.12.2021, p. 2609-2652.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
AU - Holt, Richard I. G.
AU - DeVries, J. Hans
AU - Hess-Fischl, Amy
AU - Hirsch, Irl B.
AU - Kirkman, M. Sue
AU - Klupa, Tomasz
AU - Ludwig, Barbara
AU - Nørgaard, Kirsten
AU - Pettus, Jeremy
AU - Renard, Eric
AU - Skyler, Jay S.
AU - Snoek, Frank J.
AU - Weinstock, Ruth S.
AU - Peters, Anne L.
N1 - Funding Information: RIGH serves on the speakers’ bureau for and receives research support from Novo Nordisk. He serves on the speakers’ bureau for Abbott, Eli Lilly, Otsuka and Roche. He also served as the Editor-in-Chief of Diabetic Medicine until December 2020. JHD received research funding from Afon, Eli Lilly and Novo Nordisk. He served on advisory boards for Adocia, Novo Nordisk and Zealand Pharma and was on a speaker’s bureau for Novo Nordisk. AH-F is an auditor for the ADA’s Education Recognition Program. She is a participant in a speaker’s bureau for Abbott Diabetes Care and Xeris. She is also a member of Xeris’ advisory board. IBH receives industry research funding from Medtronic Diabetes, Insulet and Beta Bionics. He is a consultant for Bigfoot, Roche and Abbott Diabetes Care. MSK receives research funding from Novo Nordisk and Bayer. TK has served on advisory boards for Abbott, Ascensia, Bioton, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Roche, Sanofi and Ypsomed. He has received research funding from Medtronic and is a participant in a speakers’ bureau for Abbott, Ascensia, Bioton, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, Roche, Sanofi and Servier. BL declares that there are no relationships or activities that might bias, or be perceived to bias, their work. KN receives research funding from, is a member of the advisory board for, and is a stockholder in Novo Nordisk. She is an advisory board member for Medtronic and Abbott Diabetes Care and receives research funding from Dexcom, Medtronic and Zealand Pharma. JP is a consultant to Sanofi, Novo Nordisk, Eli Lilly, Zealand, Mannkind and Diasome. ER serves on the advisory board for Abbott, Air Liquide SI, Dexcom, Insulet, Sanofi, Roche, Novo Nordisk and Eli Lilly, and received research support from Dexcom and Tandem. JSS is a member of the board of directors for Applied Therapeutics and Dexcom. He serves on the scientific advisory board for Abvance, ActoBiotics, Adocia, Avotres, Oramed, Orgenesis, Sanofi Diabetes, Tolerion and Viacyte. He received research support from Tolerion. He is an advisor and consultant to Boehringer Ingelheim, Dance Biopharm/Aerami Therapeutics, Enthera, Ideal Life, Imcyse, Immnomolecular Therapeutics, Novo Nordisk, Provention Bio, Sanofi Diabetes, Signos, Tolerion and VielaBio. He is a shareholder or option holder in Abvance, Avotres, Dance Biopharm/Aerami Therapeutics, Dexcom, Ideal Life, Immnomolecular Therapeutics, Oramed and Orgenesis. FJS is consultant to Abbott, Eli Lilly, Sanofi and Novo Nordisk, and serves on the speakers’ bureau for Abbott, Eli Lilly, Sanofi and Novo Nordisk. He has received research funding from Sanofi and Novo Nordisk. RSW receives research funding from Eli Lilly, Medtronic, Insulet, Diasome, Kowa, Tolerion, Novo Nordisk and Boehringer Ingelheim. ALP serves on the advisory board for Abbott Diabetes Care, Eli Lilly, Novo Nordisk, Medscape and Zealand Pharmaceuticals. She has received research support from Dexcom and Insulet and has received donated devices from Abbott Diabetes Care. She also has stock options from Omada Health and Livongo and is a special government employee of the FDA. Funding Information: The report was jointly commissioned and funded by the ADA and EASD. The authors did not receive any payment for their involvement in the writing group. Publisher Copyright: © 2021, European Association for the Study of Diabetes and American Diabetes Association.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Abstract: The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a writing group to develop a consensus statement on the management of type 1 diabetes in adults. The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycaemia, behavioural considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management and future perspectives. Although we discuss the schedule for follow-up examinations and testing, we have not included the evaluation and treatment of the chronic microvascular and macrovascular complications of diabetes as these are well-reviewed and discussed elsewhere. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this but rather aimed to highlight the major areas that healthcare professionals should consider when managing adults with type 1 diabetes. Though evidence-based where possible, the recommendations in the report represent the consensus opinion of the authors. [Figure not available: see fulltext.]
AB - Abstract: The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a writing group to develop a consensus statement on the management of type 1 diabetes in adults. The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycaemia, behavioural considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management and future perspectives. Although we discuss the schedule for follow-up examinations and testing, we have not included the evaluation and treatment of the chronic microvascular and macrovascular complications of diabetes as these are well-reviewed and discussed elsewhere. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this but rather aimed to highlight the major areas that healthcare professionals should consider when managing adults with type 1 diabetes. Though evidence-based where possible, the recommendations in the report represent the consensus opinion of the authors. [Figure not available: see fulltext.]
KW - Adjunctive therapy
KW - Diabetic ketoacidosis
KW - Diagnosis
KW - Exercise
KW - Glucose monitoring
KW - Hypoglycaemia
KW - Insulin
KW - Nutrition
KW - Psychosocial care
KW - Schedule of care
KW - Transplantation
KW - Type 1 diabetes
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85116252649&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34590174
UR - http://www.scopus.com/inward/record.url?scp=85116252649&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00125-021-05568-3
DO - https://doi.org/10.1007/s00125-021-05568-3
M3 - Article
C2 - 34590174
SN - 0012-186X
VL - 64
SP - 2609
EP - 2652
JO - Diabetologia
JF - Diabetologia
IS - 12
ER -